The Fc fusion therapeutics market is anticipated to grow at an annualized rate of over 10%, claims Roots Analysis

 Since the approval of Enbrel® in 1998 for the treatment of rheumatoid arthritis, Fc fusion therapies have evolved into a prominent class of therapeutics; currently, several therapies are being developed for a variety of disease indications

 

London

 

Roots Analysis has announced the addition of “Fc Fusion Therapeutics Market, 2021-2030” report to its list of offerings.

 

With 13 drugs approved in the European Union and the US, Fc fusion therapeutics are considered to be one of the most successful classes of IgG-based products. The success of these biopharmaceutical products can be attributed to their diverse biological and pharmacological properties, including an extended serum half-life, enhanced Fc mediated effector functions, easy expression, increased stability and aggregation resistance, modulated immunogenicity and improved safety profiles, for the treatment of a wide range of disease indications

 

To order this 130+ page report, which features 95+ figures and 140+ tables, please visit https://www.rootsanalysis.com/reports/fc-fusion-therapeutics-market.html

 

 

Key Market Insights 

 

Presently, more than 115 Fc fusion therapeutics are approved / under development

Over 60% of the aforementioned candidates are being evaluated in clinical stages; of these, 50 molecules are in advanced phases (Phase II and above) of clinical trials. This is followed by more than 30% of the Fc fusion therapeutics which are already marketed for various disease indications. It is worth noting that majority of the pipeline therapies (18) are being developed to target PD-L1 for the treatment of oncological disorders.

 

More than 25 companies claim to be engaged in the development of Fc fusion therapeutics

Post 2001, there has been a significant rise in the number of companies working in this domain. It is worth noting that majority (48%) of the firms engaged in this domain are based in North America, followed by those headquartered in Asia-Pacific (38%) and Europe (3%).

 

Over 1,450 clinical trials have been registered for the evaluation of Fc fusion therapeutics, globally 

Of these, most of the trials were / are being conducted in North America (48%). Within this region, more than 50% of the total patients were enrolled in trials focused on the evaluation of these therapeutics. This was followed by studies being conducted in Europe and Asia Pacific.

 

Close to 200 grants have been awarded to support research on Fc fusion therapeutics, since 2010

Around USD 68 million have been awarded to various organizations working in this domain, since 2010. Further, almost 80% of the total grants were awarded for a support period of 1-5 years.

 

Over 10,000 patents have been filed / granted related to Fc fusion therapeutics, since 2018

Of these, majority (45%) of the patents were filed / granted in North America, followed by Asia-Pacific (21%). Moreover, in addition to the industry players, various patents related to Fc fusion therapeutics were filed by academic institutes as well.

 

Partnership activity within this domain has grown significantly between 2015 and 2021

The maximum number of partnerships for Fc fusion therapeutics were signed in 2020. Further, product development and commercialization (32%) emerged as the most popular type of partnership model adopted by stakeholders in this domain. This was followed by product development agreements (26%), acquisitions (21%), and manufacturing and supply agreements (11%).

 

Funding and Investments within this domain has shown a significant growth between 2016 and 2021

Around USD 450 million was raised in the Fc fusion therapeutics domain, through various funding rounds. It is worth mentioning that majority of the amount (~USD 550 million) was raised through venture capital financing.

 

At present, therapies targeting ophthalmological disorders represent majority of the market share (in terms of sales revenue)

We believe that, in the foreseen future the trend is likely to remain the same. The market opportunity within this therapeutic area is likely to be distributed among indications, such as ophthalmological disorders, and hematological diseases. This is followed by genetic disorders which represent over 30% of the market share.

 

To request a sample copy / brochure of this report, please visit this link 

  

Key Questions Answered

§  Who are the leading players involved in the development of Fc fusion therapeutics?

§  Which geographies are the most active in conducting clinical trials on Fc fusion therapeutics?

§  Which are the leading funding organizations providing grants for Fc fusion therapeutics?

§  Which partnership models are commonly adopted by industry stakeholders engaged in the Fc fusion therapeutics market?

§  How is the current and future market opportunity likely to be distributed across key market segments?

 

The financial opportunity within the Fc fusion therapeutics market has been analyzed across the following segments:

§  Type of Target Indication

§  Neutropenia

§  Graft Versus Host Disease

§  Breast Cancer

§  Rheumatoid Arthritis

§  Non- Small Cell Lung Cancer

§  Neovascular (wet) Age-related Macular Degeneration (AMD)

§  Hemophilia A

§  Neuromyelitis Optica Spectrum Disorders

§  Systemic Lupus Erythematosus

 

§  Type of Fusion Molecule

  • Antibody
  • Cytokine
  • Growth Factor
  • Receptor ECD
  • Others

 

§  Type of Therapy

§  Combination

§  Monotherapy

 

§  Route of Administration (RoA)

§  Subcutaneous

§  Intravenous

§  Intravitreal

 

§  Geographical Regions 

§  North America

§  Europe

§  Asia- Pacific

§  Latin America

§  Middle East

§  Rest of the World

 

 

The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), a description of the services offered, details on recent developments and an informed future outlook.

§  Alphamab Oncology

§  Amgen

§  Acceleron Pharmaceuticals

§  Bristol-Myers Squibb

§  Sanofi

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/fc-fusion-therapeutics-market.html

or email sales@rootsanalysis.com

 

You may also be interested in the following titles: 

1.      Regulatory T-Cell Therapies (Tregs) Market, 2021–2035

2.      CD47 Targeting Therapeutics Market, 2021-2035

3.      Light Activated Therapies Market, 2021-2030

 

 

 

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

The DNA data storage market is anticipated to grow at an annualized rate of over 26% by 2035, claims Roots Analysis

  Exponential increase in amount of digital data being generated, coupled to the limitations of conventional storage mediums, has created a need for sustainable storage options and DNA data storage has garnered significant interest as an alternative   London   Roots Analysis has announced the addition of DNA Data Storage Market, 2021-2035” report to its list of offerings.   DNA as a data storage medium helps eliminate the drawbacks inherent to the traditional storage methods, such as limited storage density, instability and limited life span, making it a potential storage option for future. However, exorbitant costs, slow speed of reading and writing DNA and vulnerability to mutations or errors, may act as a roadblock in the wider use of DNA as an effective data storage solution, which has prompted the stakeholders to focus on improvements in various steps involved in DNA data storage, including data encoding, DNA synthesis, preservation, data retriev...
Read more

The CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis

  Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes.   Roots Analysis has announced the addition of “ CD-47 Targeting Therapeutics Market, 2021-2035 ” report to its list of offerings.   In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47 , owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker.   To order this 190+ page report, which features 142+ figures, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html   Key Market Insights   Over 75 CD-47 drug candidates are under various phases of development 52% of the pipeline candidates are cu...
Read more